TrialProstate cancer and prostatic diseases2026

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Quoc-Dien Trinh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.